Currently, there are several other ADC candidates developed against ovarian cancer at different stages of clinical trials, including ABBV-428, a mesothelin-CD40 bispecific [11], PF-06650808, an anti-Notch3 antibody-drug conjugate [12], and many other promising ADCs under development [13]. This evidence concerns the gene MSLN and ovarian cancer.